Book a free consultation
A no-obligation conversation with our care team, arranged through KPCIRC.
Book a consultationSignature · the monitoring-ready baseline
Signature STb O
118 genes from the same simple blood draw. Broad enough for most decisions, and broad enough to serve as your Sentinel monitoring baseline.
The balanced middle tier
STb O widens the lens to 118 genes from the same simple blood draw. Broad enough to capture most clinically relevant alterations and the immune markers, and broad enough to serve as the baseline for continuous Sentinel monitoring.
118genes for SNVs and InDels
15fusion genes
35PGx genes
What it includes
118 genes
SNVs, InDels and fusions across the panel.
Full immune profile
TMB, MSI and MMR, analytically robust at this breadth.
Copy number and signatures
Included from this tier upward.
Pharmacogenomics
The 35-gene panel, plus a tumour-fraction estimate.
Coverage by tier
The 118-gene panel
Complete coding region
71 genesThe whole coding sequence is read for these genes.
- ABL1
- AKT1
- ALK
- APC
- AR
- ARAF
- ARID1A
- ARID1B
- ATM
- ATRX
- BARD1
- BRAF
- BRCA1
- BRCA2
- BRIP1
- CDH1
- CDK12
- CDKN2A
- CHEK1
- CHEK2
- CSF1R
- CTNNB1
- EGFR
- ERBB2
- ERCC2
- ESR1
- FANCL
- FGFR1
- FGFR2
- FGFR3
- FOXL2
- HNF1A
- HRAS
- IDH1
- IDH2
- INPP4B
- KIT
- KRAS
- MET
- MLH1
- MSH2
- MSH6
- MUTYH
- NF1
- NRAS
- NTRK1
- NTRK3
- PALB2
- PDGFRA
- PIK3CA
- PMS2
- POLD1
- POLE
- PPP2R2A
- PTCH1
- PTEN
- RAD51B
- RAD51C
- RAD51D
- RAD54L
- RB1
- RET
- ROS1
- SMAD4
- SMARCB1
- SRC
- STK11
- TP53
- TSC1
- TSC2
- VHL
Hotspot regions
45 genesKnown mutation hotspots are read for these genes.
- ABL2
- ATR
- BAP1
- C11orf65
- CCND1
- CDK4
- CDX2
- DDR2
- ERBB3
- ERBB4
- EZH2
- FBXW7
- FGFR4
- FLT3
- FOXA1
- GATA3
- GNA11
- GNAQ
- GNAS
- JAK1
- JAK2
- JAK3
- KDM5C
- KDM6A
- KEAP1
- MAP2K2
- MAPK1
- MPL
- MTOR
- MYC
- MYCN
- MYD88
- NF2
- NPM1
- PBRM1
- PTPN11
- RAF1
- RHEB
- RHOA
- RIT1
- SETD2
- SF3B1
- SMO
- SPOP
- TERT
Also on the panel
2 genesOn the panel, though the source breakdown does not state which coverage tier they sit in.
- MAP2K1
- NOTCH1
Validated to include MET exon 14 skipping mutations.
Fusions and rearrangements
Fusion and rearrangement genes
15 genes- ALK
- BRAF
- EGFR
- ERBB2
- FGFR1
- FGFR2
- FGFR3
- FGFR4
- MET
- NRG1
- NTRK1
- NTRK2
- NTRK3
- RET
- ROS1
NRG1 and NTRK2 are assessed for fusions only, and are not on the 118-gene SNV panel.
The Sentinel gateway
This is the baseline Sentinel needs.
Continuous monitoring only works if there is a molecular fingerprint to track. STb O establishes that fingerprint, so Sentinel can follow your cancer over time on the same breadth. A 33-gene panel is too narrow to serve as this baseline.
Who it is for
Broad without full CGP
You want a wide profile but do not need every gene.
Planning surveillance
You anticipate monitoring and want the baseline now.
Being clear about our limits
What we do and do not do
What we DO
- Profile 118 genes with a full immune and PGx profile
- Establish the molecular baseline Sentinel needs
- Feed a complete, tumour-board-signed decision
- Support copy-number and mutational-signature analysis
What we DON’T do
- Diagnose or decide treatment on its own
- Rule out disease from a negative result
- Cover every gene in the genome
- Guarantee drug availability, approval, cover or benefit
Plain-language glossary (9 terms)
| Term | What it means |
|---|---|
| ctDNA | Circulating tumour DNA, tumour fragments in blood that a liquid biopsy reads. |
| SNV / InDel | A single-letter DNA change, or a small insertion or deletion. |
| Fusion | Two genes joined abnormally, creating a driver that is often highly treatable. |
| CNV | Copy-number variation, extra or missing copies of a gene. |
| TMB | Tumour mutational burden, how many mutations a tumour carries. |
| MSI / MMR | Signals of faulty DNA repair that often predict immunotherapy response. |
| PGx | Pharmacogenomics, how your genes affect the way you handle specific drugs. |
| Tumour fraction | How much of the blood DNA came from the tumour. |
| CCR | Complete coding region, meaning the whole gene is read rather than known hotspots. |
Important information and regulatory status
Signature STb O is a genomic (DNA-based) test for use by qualified healthcare professionals. It supports clinical judgement, it does not replace it, and it must be read alongside your full clinical history and applicable guidelines.
- A result is not a diagnosis and does not by itself decide treatment.
- A “not detected” result does not rule out cancer or a genetic change.
- Not all cancers release enough DNA into blood to be detected.
- We cannot guarantee that a medicine will be available, approved, covered or effective.
- Collection kits are for qualified phlebotomists. They are not for self-testing.
- Confirmatory testing may be required.
Regulatory status (India). Registration of our genomic tests as in-vitro diagnostic (IVD) medical devices with CDSCO is in progress, with the IVD class pending. Sequencing and variant calling are done by an accredited laboratory partner holding NABL (ISO 15189), CAP and CLIA accreditation, following ACMG/AMP/ASCO/CAP guidelines and a CE-IVD certified variant database. The OnKommon interpretation engine is provided for research and decision-support use. Marketing follows the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954.
Take the next step
Three ways forward. Pick the one that fits today.
Begin Blueprint Care
Commission your decision report and a dedicated clinical team.
Explore Blueprint CareAsk on WhatsApp, free
Signal replies to your first question within four hours, at no cost.
Start with Signal